15:12 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

FDA clarifies Movantik label

FDA updated the label for Movantik naloxegol to clarify that the compound is approved to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer...
00:43 , Mar 25, 2017 |  BioCentury  |  Finance

Solasia goes to market

After becoming the first Japanese biotech to go public in 18 months, Solasia Pharma K.K. (Tokyo:4597) plans to use the proceeds to prepare to launch its first products in China. Solasia raised ¥3.6 billion ($32...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Kyowa Hakko Kirin deal

AstraZeneca granted Kyowa’s ProStrakan Group plc subsidiary exclusive rights to develop and commercialize Moventig naloxegol in the EU, Iceland, Norway, Switzerland and Liechtenstein. AZ has exclusive, worldwide rights to the PEGylated form of naloxol, a...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Solasia, Lee’s Pharmaceutical Holdings Ltd. deal

Solasia granted Lee’s exclusive rights to commercialize Sancuso granisetron patch to treat chemotherapy-induced nausea and vomiting (CINV) in China, excluding Hong Kong and Macau. Solasia retains rights to promote the transdermal serotonin (5-HT3) receptor antagonist...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Archimedes Pharma, Kyowa Hakko Kirin deal

Kyowa’s ProStrakan Group plc subsidiary completed its acquisition of Archimedes from life science investor Novo A/S for L230 million ($384.9 million) in cash (see BioCentury, July 14). Archimedes Pharma Ltd. , Reading, U.K.   Kyowa...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Kyowa Hakko Kirin Co. Ltd, Archimedes Pharma deal

Kyowa’s ProStrakan Group plc subsidiary will acquire Archimedes from life science investor Novo A/S for L230 million ($394.4 million) in cash. Archimedes has technologies for nasal and oral drug delivery and markets products in the...
00:28 , Jul 12, 2014 |  BC Extra  |  Company News

Kyowa's ProStrakan subsidiary to acquire Archimedes

The ProStrakan Group plc subsidiary of Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will acquire Archimedes Pharma Ltd. (Reading, U.K.) from Novo A/S for L230 million ($394.4 million) in cash. Archimedes has technologies for nasal and...